Hormonal approaches to the chemoprevention of endocrine-dependent tumors

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The estrogen dependency of human breast cancer has been successfully exploited in the treatment of early and advanced diseases and provides a unique opportunity for chemoprevention of this common malignancy. Preliminary results with the antiestrogens Tamoxifen and Raloxifene show an encouraging reduction in the incidence of breast cancer. Alternative approaches include the use of highly selective and non-toxic aromatase inhibitors and, in premenopausal women, the use of LHRH agonists in conjunction with the administration of small doses of estrogen and progesterone. The rationale for these chemopreventive strategies and their possible limitations are briefly discussed.

Original languageEnglish (US)
Pages (from-to)483-485
Number of pages3
JournalEndocrine-Related Cancer
Volume6
Issue number4
DOIs
StatePublished - Dec 1999

Fingerprint

Chemoprevention
Estrogens
Breast Neoplasms
Aromatase Inhibitors
Estrogen Receptor Modulators
Tamoxifen
Gonadotropin-Releasing Hormone
Progesterone
Neoplasms
Incidence
Therapeutics
Raloxifene Hydrochloride

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

@article{07197423949046c4b9facc3cbdc6ecfb,
title = "Hormonal approaches to the chemoprevention of endocrine-dependent tumors",
abstract = "The estrogen dependency of human breast cancer has been successfully exploited in the treatment of early and advanced diseases and provides a unique opportunity for chemoprevention of this common malignancy. Preliminary results with the antiestrogens Tamoxifen and Raloxifene show an encouraging reduction in the incidence of breast cancer. Alternative approaches include the use of highly selective and non-toxic aromatase inhibitors and, in premenopausal women, the use of LHRH agonists in conjunction with the administration of small doses of estrogen and progesterone. The rationale for these chemopreventive strategies and their possible limitations are briefly discussed.",
author = "A. Manni",
year = "1999",
month = "12",
doi = "10.1677/erc.0.0060483",
language = "English (US)",
volume = "6",
pages = "483--485",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "4",

}

Hormonal approaches to the chemoprevention of endocrine-dependent tumors. / Manni, A.

In: Endocrine-Related Cancer, Vol. 6, No. 4, 12.1999, p. 483-485.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hormonal approaches to the chemoprevention of endocrine-dependent tumors

AU - Manni, A.

PY - 1999/12

Y1 - 1999/12

N2 - The estrogen dependency of human breast cancer has been successfully exploited in the treatment of early and advanced diseases and provides a unique opportunity for chemoprevention of this common malignancy. Preliminary results with the antiestrogens Tamoxifen and Raloxifene show an encouraging reduction in the incidence of breast cancer. Alternative approaches include the use of highly selective and non-toxic aromatase inhibitors and, in premenopausal women, the use of LHRH agonists in conjunction with the administration of small doses of estrogen and progesterone. The rationale for these chemopreventive strategies and their possible limitations are briefly discussed.

AB - The estrogen dependency of human breast cancer has been successfully exploited in the treatment of early and advanced diseases and provides a unique opportunity for chemoprevention of this common malignancy. Preliminary results with the antiestrogens Tamoxifen and Raloxifene show an encouraging reduction in the incidence of breast cancer. Alternative approaches include the use of highly selective and non-toxic aromatase inhibitors and, in premenopausal women, the use of LHRH agonists in conjunction with the administration of small doses of estrogen and progesterone. The rationale for these chemopreventive strategies and their possible limitations are briefly discussed.

UR - http://www.scopus.com/inward/record.url?scp=0033393713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033393713&partnerID=8YFLogxK

U2 - 10.1677/erc.0.0060483

DO - 10.1677/erc.0.0060483

M3 - Article

C2 - 10730902

AN - SCOPUS:0033393713

VL - 6

SP - 483

EP - 485

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 4

ER -